BioSpace News Archive

As per Precedence Research, The healthcare information systems market size is expected to surpass around US$ 487.8 billion by 2030 and expanding growth at a CAGR of 7.8% from 2022 to 2030.

The population health management market size is expected to surpass around US$ 152.2 billion by 2029 and growing at a CAGR 20.5% over the forecast period 2021 to 2030.

Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered into an agreement under which Pyxis Oncology will be granted an exclusive license to develop and commercialize Biosion’s anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as PYX-106), world-wide, excluding Greater China.

Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes, have invested in the company.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that is has received clearance from the U.S. Food & Drug Administration (FDA) to market SImpact SI Joint Fixation System for Posterior-Oblique approaches.

BioCurity is a private preclinical biotech company developing supportive cancer oncology drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

The National Cancer Institute-designated Albert Einstein Cancer Center has announced the appointment of three faculty members to key leadership positions, reflecting the center’s commitment to basic science, translational, and clinical research and its core principles of diversity, equity, and inclusion.

Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes.

Geron Corporatio announced that it intends to offer and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of its common stock, pre-funded warrants to purchase shares of its common stock, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering.

AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.